- Home
- HTO vs PVLA Comparison
HTO vs PVLA Comparison
Compare HTO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | PVLA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | 837 | 29 |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HTO | PVLA |
|---|---|---|
| Price | $66.84 | $138.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $62.00 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 477.0K | 234.4K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | $104,350.18 |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.75 | $34.57 |
| 52 Week High | $66.05 | $161.38 |
Technical Indicators
Market Signals| Indicator | HTO | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 50.46 |
| Support Level | $55.76 | $106.07 |
| Resistance Level | N/A | $156.88 |
| Average True Range (ATR) | 1.34 | 11.21 |
| MACD | 0.06 | -1.87 |
| Stochastic Oscillator | 88.70 | 49.86 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.